Skip to main content
letter
. 2016 Sep 20;30(12):2419–2422. doi: 10.1038/leu.2016.245

Table 1. Characteristics of CLL clonotypes and mimotopes.

Patient Clonotype mIgCLLa VHDJH VLJL CDR3 lengthb VH CDR3 IMGT aa sequencec Freq. (%)d Stereotypic subsete Mimotope name Mimotope aa sequence KD (nm)f
CLL#1 CLL1 mIgCLL1 V3-11/D3-10/J6 κV1-39(1D-39)/J2 17 AREGLWFGELSYYGMDV 100 NA pCLL1 CSPAKELGC 34.03
CLL#2 CLL2 mIgCLL2-1 V3-73/D3-3/J6 κV1-33(1D-33)/J1 20 TFDFWSGYYDGYYYYYGMDV 80 NA pCLL2-1 CNTYSVSLC 10.81
    mIgCLL2-2       TFDFWSGYYDGYYYYYGLDF 20   pCLL2-2 CKSYSVSLC 7.57
CLL#3 CLL3 mIgCLL3-1 V3-23/D3-22/J4 κV1-8(1D-8)J3 17 AKRDYSHRSDYAPLFEY 90 NA pCLL3-1 CPPQSVTEC 22.14
    mIgCLL3-2       GKRDYSHSSDYAPLFEY 10 NA pCLL3-2 CDVWHSAYC 5.64
CLL#4-1 CLL4-1 mIgCLL4-1 V4-34/D7-27/J2 κV1-33(1D-33)/J1 17 ARRGTGDPPYWYFDL 77 NA pCLL4-1 CTTNPADSC 5.50
CLL#4-2 CLL4-2 mIgCLL4-2 V4-4/D6-19/J2 κV2-28(2D-28)J1 21 ARGTVGQQWLEVLDWYFGL 23 NA pCLL4-2 CVLWWSPIC 3.90
CLL#5-1 CLL5-1 mIgCLL5-1 V4-34/D3-22/J4 κV1D-12/J1 20 ARGGNNDKIVMLLYYFDF 57 NA pCLL5-1 CFSDDEWWC 7.08
CLL#5-2 CLL5-2 mIgCLL5-2 V4-59/D3-22/J3 κV1-13(1D-13)/J2 18 ARDYDYDTRKSDAFDIW 43 NA pCLL5-2 CPPFTNYEC 7.32
CLL#6-1 CLL6-1 mIgCLL6-1 V1-46/D3-10/J6 κV3D-15/J1 22 ARDWVATMVRGVIESRPTGMDV 65 NA pCLL6-1 CNQDWHKKC 57.53
CLL#6-2 CLL6-2 mIgCLL6-2 V4-34/D2-2/J6 κV1D-17/J1 24 ASRFYCSGSSCEAPRYYYYYGLDV 35 16 pCLL6-2 CTTVIPERC 22.67
a

Name of the CLL-derived monoclonal Igγ1 antibodies expressing the indicated VHDJH and VLJL rearrangements.

b

Number of amino acids of the VH CDR3.

c

VH CDR3 amino acid sequence according to the International ImMunoGeneTics information system (http://www.imgt.org).

d

Percentage of analyzed cells expressing the indicated VH CDR3.

e

Stereotypic subset according to Agathangelidis et al.5 NA, not attributable to a currently defined stereotypic subset.

f

KD values for the mimotope binding to the cognate mIgCLL, as estimated by the Scatchard plot analysis.